Dr. Welty has over 25 years’ experience in preclinical and clinical pharmacology leading organizations and projects teams from early discovery to approval and commercialization, most recently as the Global Head of DMPK, Shire. He has supported the successful submission of more than 50 IND/CTAs and more than 20 NDA/MAA/BLAs for small molecules, biologics and gene therapy therapeutics. He has extensive experience in pharmacokinetics, pharmacodynamics and systems pharmacology and adopting model-informed approaches for candidate nomination and efficient clinical development strategy.
His therapeutic area experience includes neurology, ophthalmology for anterior and posterior retinal diseases, and rare disease therapeutics including lysosomal storage diseases, hereditary angioedema, short-bowel syndrome and hemophilia.
Education